C. Westland

发表

Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach

J. Pérez-Ruixo, O. Ackaert, S. Ouwerkerk-Mahadevan, 2018, The AAPS Journal.

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

J. Pérez-Ruixo, O. Ackaert, S. Ouwerkerk-Mahadevan, 2018, The AAPS Journal.

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.

Huiling Yang, W. Delaney, C. Westland, 2004, Antiviral research.

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Michael D. Miller, C. Gibbs, E. Arnold, 2003, Journal of Virology.

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003, Hepatology.

ElotuzumabinCombinationWithLenalidomideandLow-Dose DexamethasoneinRelapsedorRefractoryMultipleMyeloma

S. Jagannath, S. Lonial, R. Vij, 2012 .

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

S. Jagannath, S. Lonial, R. Vij, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

S. Jagannath, S. Lonial, R. Vij, 2010 .

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

W. Talloen, P. Tangkijvanich, E. Gane, 2022, Journal of Antimicrobial Chemotherapy.

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

W. Talloen, E. Gane, J. Snoeys, 2021, Antiviral therapy.

Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects

A. Patat, Qingling Zhang, T. Kakuda, 2018, Pharmacology research & perspectives.

Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

S. Jagannath, S. Lonial, R. Vij, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

C. Gibbs, J. Villeneuve, F. Zoulim, 2003, Journal of hepatology.

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003, Hepatology.

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

C. Gibbs, P. Marcellin, R. Gish, 2003, Gastroenterology.

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.

J. Hulot, H. Izzedine, G. Deray, 2004, Kidney international.

Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC)

S. Sarafianos, C. Gibbs, Huiling Yang, 2001, Journal of Virology.

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

C. Gibbs, Huiling Yang, C. Westland, 2000, Hepatology.

Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

C. Gibbs, Huiling Yang, W. Delaney, 2002, Hepatology.

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

C. Gibbs, P. Marcellin, R. Gish, 2003 .

Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, A. Neumann, 2003 .

Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients

M. Wulfsohn, C. Gibbs, W. Delaney, 2005, Journal of viral hepatitis.

1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy

Michael I. Miller, M. Wulfsohn, C. Gibbs, 2002 .

Lack of emerging resistance mutations in 467 HBeAg− and HBeAg+ patients with chronic hepatitis B receiving Adefovir Dipivoxil for 48 weeks

C. Gibbs, Huiling Yang, W. Delaney, 2002 .

382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase

C. Gibbs, E. Arnold, K. Das, 2004 .

Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003 .

Dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral CL

C. Gibbs, Huiling Yang, E. Heathcote, 2001 .

45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients

P. Marcellin, M. Shiffman, M. Rizzetto, 2004 .

HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir

C. Gibbs, Huiling Yang, J. Toole, 1998 .

Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003 .

10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment

M. Wulfsohn, J. Villeneuve, F. Zoulim, 2003 .

Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach

J. Pérez-Ruixo, O. Ackaert, S. Ouwerkerk-Mahadevan, 2018, The AAPS Journal.

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

A. Patat, Qingling Zhang, A. Streinu-Cercel, 2018, PloS one.

FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers

W. Talloen, P. V. Remoortere, E. Gane, 2019, Journal of Hepatology.

Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo

L. Mucke, E. Masliah, M. Mallory, 1997, Neuroscience.

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Rob Lambkin-Williams, Qingling Zhang, J. Symons, 2015, The New England journal of medicine.

Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein.

R. D'Hooge, L. Mucke, G. Nagels, 1996, Neuroreport.

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

S. Jagannath, S. Lonial, R. Vij, 2010 .

Novel role of human CD4 molecule identified in neurodegeneration

L. Mucke, E. Masliah, T. Wyss-Coray, 1998, Nature Medicine.

Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

M. Yuen, J. Niu, Qingling Zhang, 2022, Journal of Hepatology.

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

J. Pérez-Ruixo, O. Ackaert, S. Ouwerkerk-Mahadevan, 2018, The AAPS Journal.

LB-1Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study

Rob Lambkin-Williams, Qingling Zhang, J. Symons, 2014 .